GE HealthCare Said to Be in Talks for $1 Billion Sofie Biosciences Deal

GE HealthCare Technologies is in discussions to acquire Sofie Biosciences, a developer of radiopharmaceuticals, in a deal that could be valued at about $1 billion, according to people familiar with the matter.

The talks were first reported on Sunday. The potential transaction, if completed, would add a radiopharmaceutical developer to GE HealthCare's portfolio as the company continues to expand its presence in medical imaging and related technologies.

Radiopharmaceuticals are used in diagnostic imaging and targeted therapies, a segment that has drawn increasing interest from large healthcare and life sciences companies in recent years.

Details of the negotiations, including the stage of the discussions and the structure of any agreement, were not immediately available. The reported talks have not been confirmed by either company, and it remains unclear whether a deal will be reached.

The development comes as GE HealthCare Technologies, a major player in medical imaging and diagnostics, looks to deepen its capabilities in specialized areas of healthcare technology.